In addition, whilst the BCL-2 over-expressing lymphoma lines were less sensitive overall to treatment with the MCL-1 inhibitor S63845 than control Eμ-Myc lymphoma lines, some of the BCL-2 expressing lines that displayed lower venetoclax sensitivity were still similarly sensitive to the MCL-1 inhibitor as control Eμ-Myc lymphomas (Fig. 5e and Supplementary Fig. 10c, d and Supplementary Table 1). This evidence concerns the gene MCL1 and lymphoma.